# AOD-9604 Philippines: Growth Hormone Fragment Guide Source: https://www.philippinespeptides.com/peptides/aod9604 Updated: 2026-09-24 > AOD-9604 Philippines guide: a human growth hormone fragment (hGH 176-191) studied in animal work and a phase 2b obesity trial. Side effects and status. On this page - [What is AOD-9604](#what) - [How it works](#how) - [On the ground in the Philippines](#ph-context) - [Benefits studied](#benefits) - [Side effects reported](#side-effects) - [Regulatory status](#regulatory) - [Who should not use AOD-9604](#contraindications) - [FAQ](#faq) - [Where to get AOD-9604 in the Philippines](#sourcing) - [Primary sources](#sources) Weight loss · Compound # AOD-9604 Philippines Peptides editorial desk Updated 24 September 2026 Trial data checked 23 September 2026 6 min read 5 sources **Class** - Metabolic research AOD-9604 is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does. ## What is AOD-9604 AOD-9604 is a synthetic peptide fragment derived from the C-terminal end of human growth hormone, amino acids 176 to 191. Researchers isolated this region because, in animal and tissue studies (Ng 2000; Heffernan 2001), it was associated with growth hormone's effects on fat metabolism. Browse the full [peptide library](https://www.philippinespeptides.com/peptides) for related compounds. Phosphagenics Limited ran a phase 2b randomised, placebo-controlled trial of AOD-9604 in obese adults with a 12-week endpoint (2007). A 2013 paper (Stier et al.) reviewed its safety and tolerability data in humans. AOD-9604 had no Philippine drug registration in the FDA Philippines database when checked on 7 May 2026. [GLP-1 peptides](https://www.philippinespeptides.com/weightloss) act on hormone receptors involved in appetite. The AOD-9604 studies cited on this page examined fat breakdown (lipolysis) and fat storage (lipogenesis) in animal and tissue models instead. [Tesamorelin](https://www.philippinespeptides.com/peptides/tesamorelin), a growth hormone-releasing hormone analogue, is covered on its own page. Our partner and supplier If you decide to source research peptides Research vials are not approved for human use, are sold for research only, and must be reconstituted. - Stocked in Metro Manila; same-day delivery there for orders before 12 noon - Lab report: Janoshik, batch RETA-4728-A, retatrutide, bacterial endotoxin only; not identity or purity. Key [H2KI86I8GWB4](https://verify.janoshik.com/tests/234146_H2KI86I8GWB4), [batch reports](https://www.primaralabs.com/coa?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=bridge&utm_content=aod9604) - [60-day money-back guarantee](https://www.primaralabs.com/guarantee?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=bridge&utm_content=aod9604) - GCash, Maya, QR Ph bank transfer, InstaPay Primara Labs is our partner and supplier. ## How it works Lipolysis: in animal and tissue studies (Ng 2000; Heffernan 2001), AOD-9604 increased the breakdown of stored fat into free fatty acids. These are animal and tissue findings. Lipogenesis: the same animal and tissue studies examined the conversion of nutrients into stored fat, which the fragment reduced. Beta-3 adrenergic receptors: a 2001 mouse study (Heffernan et al.) compared obese mice with mice lacking the beta-3 adrenergic receptor to examine whether the fragment's effects on fat metabolism depend on that receptor. ## On the ground in the Philippines AOD-9604 had no Philippine drug registration in the FDA Philippines registered drug products database when it was checked on 7 May 2026. ## Benefits studied AOD-9604 is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does. Anything published about it elsewhere should be read with its evidence level in mind: most peptides in this category have animal or cell data only. ## Side effects reported No controlled human data on adverse events for AOD-9604 is in the datasets this site draws on, so its safety in people is unknown rather than established. Effects commonly described for it are listed below; how often they occur has not been measured in a controlled trial. - Injection site redness or swelling - Flushing or warmth after injection - Fatigue - Headache - Dizziness after injection - Nausea ## Regulatory status The regulatory dataset this site draws on has no row for AOD-9604. ## Who should not use AOD-9604 Do not use if - Active cancer or history of cancer - Pregnancy or breastfeeding - Under 18 years old - Diabetes - Allergy to peptide components Everything above is research framing. If you have got as far as wanting a vial, the catalogue at Primara Labs, our partner and supplier, is the shortest way to see what is held inside the Philippines and at what price. [View the Primara Labs catalogue](https://www.primaralabs.com/marketplace?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline) Primara Labs, our partner and supplier, stocks its research catalogue in Metro Manila. Research use only. ## FAQ ### What evidence exists for AOD-9604? The sources cited on this page are animal and tissue studies of fat metabolism (Ng 2000; Heffernan 2001), a phase 2b randomised, placebo-controlled trial in obese adults with a 12-week endpoint (2007), and a 2013 paper on safety and tolerability in humans (Stier et al.). AOD-9604 is not in the evidence datasets this site draws on, so no benefit or trial figure is shown on this page. ### How does AOD-9604 differ from GLP-1 peptides? GLP-1 peptides such as retatrutide and tirzepatide act on hormone receptors involved in appetite and blood sugar. The AOD-9604 studies cited on this page examined fat breakdown and fat storage in animal and tissue models. No trial comparing AOD-9604 with a GLP-1 peptide is cited here. ### Is AOD-9604 registered in the Philippines? ## Where to get AOD-9604 in the Philippines Primara Labs, our partner and supplier, lists their current vials on the catalogue. Prices and stock change, so check there for what is available now. [View the Primara Labs catalogue](https://www.primaralabs.com/marketplace?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline) Our partner and supplier ### Sourcing peptides in the Philippines Primara Labs, our partner and supplier, ships from inventory already inside the Philippines, so there is no customs leg: vials are batch-numbered, Metro Manila orders dispatch same day, the rest of the country lands in 1 to 5 business days, and the store lists 10% off every order. The current list sits on one page, and anything you cannot see on it goes through the same WhatsApp thread. The supply index covers what to ask a seller before paying, and why quoted prices vary so widely. [View Supply Index](https://www.philippinespeptides.com/supply) ## Primary sources Citations supporting the clinical claims on this page. Each entry links to the primary record. - 1. AOD-9604 mechanism: Heffernan 2001 Mechanism Heffernan M, Summers RJ, Thorburn A, et al. "The effects of human growth hormone and its lipolytic fragment (AOD9604) on lipid metabolism." Endocrinology 2001;142(12):5182–5189. [DOI: 10.1210/endo.142.12.8522](https://doi.org/10.1210/endo.142.12.8522) - 2. Lipolytic domain metabolic studies: Ng 2000 Mechanism Ng FM, Sun J, Sharma L, et al. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Horm Res 2000;53(6):274–278. [PMID: 10970609](https://pubmed.ncbi.nlm.nih.gov/10970609/) - 3. Phase 2b obesity trial: AOD-9604 Trial Phosphagenics Limited Phase 2b randomised, placebo-controlled trial of AOD9604 in obese subjects; 12-week endpoint analysis (2007). [PMID: 17299057](https://pubmed.ncbi.nlm.nih.gov/17299057/) - 4. AOD-9604 safety and tolerability: Stier 2013 Trial Stier H, Vos E, Kenley D. "Safety and tolerability of the hexadecapeptide AOD9604 in humans." J Endocrinol Metab 2013;3:7–15. [Source](https://www.scirp.org/journal/paperinformation?paperid=27897) - 5. FDA Philippines drug registry: AOD-9604 not listed Reference FDA Philippines Registered Drug Products Database. Verified 2026-05-07: AOD-9604 has no Philippine drug registration; available only as research-grade peptide. [Source](https://verification.fda.gov.ph/) How this was gathered Findings, evidence levels and sources are from the Research Desk datasets published by [Primara Labs, our partner and supplier](https://www.primaralabs.com/research/evidence?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline), synced 23 September 2026 and summarised here in this site’s own words. Risk · Disclosure · Editorial Status This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy. In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale. **Editorial Status** - Non-clinical **Affiliation** - Not a clinic · Not a pharmacy **Last Updated** - September 24, 2026 ### Related peptides - [Compound Retatrutide](https://www.philippinespeptides.com/peptides/retatrutide) - [Compound 5-Amino-1MQ](https://www.philippinespeptides.com/peptides/5-amino-1mq) - [Compound Tesamorelin](https://www.philippinespeptides.com/peptides/tesamorelin) - [Compound CJC-1295 (DAC)](https://www.philippinespeptides.com/peptides/cjc1295-dac) --- Philippines Peptides sells nothing. Primara Labs is our partner and supplier. This is general information, not medical or legal advice.